Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine

No licensed vaccine is available for prevention of EBV-associated diseases, and robust, high-throughput bioanalytical assays are needed to evaluate immunogenicity of gp350 subunit-based candidate EBV vaccines. Here we have developed an improved EBV-GFP based neutralization assay for such a vaccine’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui, Gemmell, Lorraine, Lin, Rui, Zuo, Fengrong, Balfour, Henry H., Woo, Jennifer C., Hayes, Gregory M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059750/
https://www.ncbi.nlm.nih.gov/pubmed/32180911
http://dx.doi.org/10.4084/MJHID.2020.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059750/
https://www.ncbi.nlm.nih.gov/pubmed/32180911
http://dx.doi.org/10.4084/MJHID.2020.016

Ejemplares similares